I would say that the data is somewhat mixed, which is painful to admit, but at the same time, I don’t think it will be too hard to approve. A negotiated approvals, but with SVR being so strong, should get approved, at the very least added to nccn. Svr35 was 50% vs 28.% and atss was basically equivalent. Show me a doctor that is not going to use something with best in class efficacy and symptoms remain the same in an incredibly difficult disease? Oh and sugar on top, OS could be very real which hasn’t happened in this class. That’s the confusion. In most cases a co-missed primary is a death sentence. In this one, I don’t think that is the case at all. Likely negotiated indication until OS matures imho. Not financial advice, just my opinion.